Haydale to provide HT200 Plasma Reactor to U.S-based 401 Tech Bridge

Haydale has announced that it has partnered with U.S-based 401 Tech Bridge to provide a HT200 Plasma Reactor and advanced materials support for their innovation ecosystem.

The HT200 Plasma Reactor will be utilized in the 401 Tech Bridge Advanced Materials and Technology Center, managed by the University of Rhode Island (URI), to support material commercialization efforts of Graphene Composites and other local composites and textiles-based businesses. This adds to 401 Tech Bridge's capability supporting its ambition to accelerate the adoption of new materials and support companies' efforts in developing new products.

 

The HT200 incorporates Haydale's patented functionalization technologies which will be utilized by Graphene Composites, a nano-materials engineering company, for its newly developed anti-viral GC Ink and other products. GC Ink has been independently tested by Brown University in Rhode Island to show effectiveness at neutralizing coronavirus and influenza viruses in under one minute.

Christian Cowan, Tech Bridge 401 Executive Director, said: "Installing the Haydale equipment in the 401 Tech Bridge Advanced Materials & Technology Center will make it available to companies that are doing advanced materials research, enabling innovation and economic growth. We're pleased to partner with Haydale, and to be working with Graphene Composites as they bring the GC Ink to market."

Sandy Chen, Graphene Composites CEO & Co-Founder, said: "Having the ability to access the Haydale technology and unique innovation facilities at 401 Tech Bridge is a significant advancement to full commercialization of our GC Ink as a powerful weapon against this pandemic and supporting the safe reopening of schools and public spaces."

Keith Broadbent, Haydale CEO, added: "We are pleased to be working with 401 Tech Bridge and look forward to our technology helping the adoption of nanotechnology in composites in Rhode Island. Specifically, the increased global focus on a need for viral efficacy, it is great to see Haydale's patented functionalization process play such a key role in a solution."

Posted: Mar 29,2021 by Roni Peleg